The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer

Alison Backen, Andrew G. Renehan, Andrew R. Clamp, Carlo Berzuini, Cong Zhou, Amit M. Oza, Selina Bannoo, Stefan Scherer, Rosamonde E. Banks, Caroline Dive, Gordon C. JaysonClinical 2014 · DOI

Abstract

The combined values of Ang1 and Tie2 are predictive biomarkers for improved PFS in bevacizumab-treated patients with ovarian cancer. These findings need to be validated in larger trials due to the limitation of sample size in this study.
BibTeX
@inproceedings{backen2014combination,
  author = {Alison Backen and Andrew G. Renehan and Andrew R. Clamp and Carlo Berzuini and Cong Zhou and Amit M. Oza and Selina Bannoo and Stefan Scherer and Rosamonde E. Banks and Caroline Dive and Gordon C. Jayson},
  title = {{The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer}},
  booktitle = {Clinical},
  year = {2014},
  doi = {10.1158/1078-0432.ccr-13-3248},
}

Loading related content...

Figure